Wandercraft, a French company specializing in medical exoskeletons, has acquired Ekso Bionics, an American leader in the field. This acquisition, announced and finalized on October 1, 2026, unites four exoskeleton models under one company. The boards of directors of both Wandercraft and ChronoScale Holdings, the parent company of Ekso Bionics, approved the deal unanimously. The financial details of the acquisition were not disclosed. Wandercraft, founded in Paris in 2012, developed the Atalante exoskeleton and is known for its use of artificial intelligence in robotics. Ekso Bionics, based in San Francisco, has been designing exoskeletons for about 20 years and was previously a subsidiary of ChronoScale Holdings, a publicly traded company on the Nasdaq stock exchange. The merger brings together two major players in robotic rehabilitation, with a global presence in over 700 centers. Wandercraft is expanding into the United States, where it currently sells its personal exoskeleton, Eve. Ekso Bionics contributes its commercial network and clinical experience in the U.S., while Wandercraft brings its expertise in Europe, the Middle East, and Africa. The two companies will combine their products, teams, and clinical partnerships across the Atlantic. Wandercraft's Atalante X is used in over 150 rehabilitation centers, while Ekso Bionics' EksoNR is used in more than 700 centers worldwide. Together, these exoskeletons are approved in the U.S. and Europe for conditions such as strokes, spinal cord injuries, multiple sclerosis, and acquired brain injuries. For home use, Wandercraft's Eve, a self-balancing exoskeleton, was the first personal model of its kind authorized by the FDA and has been sold in the U.S. since mid-September. Ekso's Indego Personal is a modular exoskeleton designed for people with spinal cord injuries, available on medical prescription. Wandercraft plans to continue offering four exoskeletons, two for hospital use and two for home use. In the U.S., Medicare may reimburse personal exoskeletons under certain conditions, as they are classified as orthoses. Wandercraft is training patients at its "Walk in New York" center and assisting users with procedures involving doctors and insurers, including financing solutions. The company aims to advocate for better coverage globally. Wandercraft CEO Matthieu Masselin emphasized the goal of bringing products, teams, and clinical relationships together across the Atlantic to help more people experience independence and connection through standing and walking. Ekso Bionics CEO Scott Davis described the merger as an "exciting new chapter" for the company, which has spent two decades accumulating research and clinical evidence. The merger also strengthens Wandercraft's position in the industry, including its development of the humanoid robot Calvin-40, currently being tested at the Renault plant in Douai. Rehabilitation centers will be able to consult specialists trained on both machines while maintaining specific assistance for each product.